Document is current

Article History

Accepted: 9 February 2025

First Online: 21 March 2025

Declarations

:

: This review was supported by funds made available through the Office of Faculty Research and Development of the Burnett School of Medicine at Texas Christian University.

: Lucy Eletel, Talia Thomas, and Emily A. Berry have no conflicts of interest that are directly relevant to the content of this article. Gregory L. Kearns is a consultant in pediatric clinical pharmacology for Tellus Therapeutics, a US corporation engaged in drug development for neonates. Gregory L. Kearns is an Editorial Board member of Pediatric Drugs. Professor Kearns was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Not applicable.

: Not applicable.

: Not applicable.

: The literature search engines used to support the development of this work were PubMed Central and EMBASE. An artificial intelligence search engine (ChatGPT v4.0) was used to assist in the creation of the data table.

: Not applicable.

: Under the guidance of GLK and EAB, LE and TT were responsible for creating the first draft of the manuscript. EAB and GLK provided additional content to the paper and were responsible for the final editing prior to submission.